Edwin Roger Parra
Impact in
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- Immunology top 1%
- Immunotherapy and Immune Responses
- Immune cells in cancer
Papers in
- Oncology 80
- Cancer Immunotherapy and Biomarkers 52
- CAR-T cell therapy research 19
- Cancer Cells and Metastasis 11
- Immunology 33
- Immunotherapy and Immune Responses 24
- Immune cells in cancer 9
- Co-authors
- Ignacio Ivan Wistuba (34 shared papers)Jaime Rodriguez‐Canales (14 shared papers)Don Lynn Gibbons (10 shared papers)Carmen Behrens (11 shared papers)Jing Wang (6 shared papers)Lixia Diao (4 shared papers)Lauren Byers (4 shared papers)John Victor Heymach (8 shared papers)
- Journals
- Clinical Cancer Research (16 papers)Journal for ImmunoTherapy of Cancer (11 papers)Nature Communications (11 papers)Cancer Discovery (7 papers)Cancers (7 papers)
- Partner nations
- United StatesBrazilJapan
In The Last Decade
Edwin Roger Parra
161 papers receiving 11.5k citations
Edwin Roger Parra's Hit Papers
Peers
Comparison fields: 5 of 125
- Oncology 5.8k
- Immunology 2.4k
- Cancer Research 1.6k
- Pulmonary and Respiratory Medicine 3.2k
- Molecular Biology 3.0k
Countries citing papers authored by Edwin Roger Parra
This map shows the geographic impact of Edwin Roger Parra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edwin Roger Parra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edwin Roger Parra more than expected).
Fields of papers citing papers by Edwin Roger Parra
This network shows the impact of papers produced by Edwin Roger Parra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edwin Roger Parra. The network helps show where Edwin Roger Parra may publish in the future.
Co-authors
The 25 scholars most cited alongside Edwin Roger Parra, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 164 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma Hit paper breakdown → | 2018 | 1296 |
| 2 | Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities Hit paper breakdown → | 2015 | 770 |
| 3 | Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial Hit paper breakdown → | 2020 | 649 |
| 4 | Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis Hit paper breakdown → | 2018 | 616 |
| 5 | Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial Hit paper breakdown → | 2021 | 488 |
| 6 | A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition Hit paper breakdown → | 2015 | 391 |
| 7 | 2016 | 374 | |
| 8 | 2020 | 340 | |
| 9 | A proteogenomic portrait of lung squamous cell carcinoma Hit paper breakdown → | 2021 | 272 |
| 10 | 2017 | 215 | |
| 11 | 2020 | 214 | |
| 12 | 2015 | 188 | |
| 13 | Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial Hit paper breakdown → | 2023 | 173 |
| 14 | 2016 | 172 | |
| 15 | 2020 | 170 | |
| 16 | 2017 | 163 | |
| 17 | 2020 | 158 | |
| 18 | MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma Hit paper breakdown → | 2023 | 141 |
| 19 | 2016 | 134 | |
| 20 | 2017 | 128 |
About Edwin Roger Parra
Edwin Roger Parra is a scholar working on Oncology, Immunology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Cancer Research, having authored 164 papers that have together received 11.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (52 papers), Immunotherapy and Immune Responses (24 papers), CAR-T cell therapy research (19 papers), Lung Cancer Treatments and Mutations (12 papers), Cancer Cells and Metastasis (11 papers), Cancer Genomics and Diagnostics (10 papers), Immune cells in cancer (9 papers) and Single-cell and spatial transcriptomics (8 papers). The work is most often cited by research in Oncology (5.8k citations), Immunology (2.4k citations), Cancer Research (1.6k citations), Pulmonary and Respiratory Medicine (3.2k citations) and Molecular Biology (3.0k citations). Edwin Roger Parra has collaborated with scholars based in United States, Brazil and Japan. Frequent co-authors include Ignacio Ivan Wistuba, Jaime Rodriguez‐Canales, Don Lynn Gibbons, Carmen Behrens, Jing Wang, Lixia Diao, Lauren Byers, John Victor Heymach, Barbara Mino and Limo Chen. Their work appears in journals such as Clinical Cancer Research, Journal for ImmunoTherapy of Cancer, Nature Communications, Cancer Discovery and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.